Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sonke Pharmaceuticals, the South Africa-based joint venture (JV) of Ranbaxy Laboratories, has received a government order to supply anti-retroviral (ARV) drugs worth R913.5m (INR6.03bn) for a period of two years.
Subscribe to our email newsletter
Recently, the South African government has floated a R4.28bn national ARV drugs tender.
Sonke Pharmaceuticals, a JV between Ranbaxy (Pty) (70% stake) and Community Investment Holdings (30% stake), is a local supplier of generic ARV medication in South Africa.
The drugs will be manufactured in South Africa and at Ranbaxy facilities, in India, Ranbaxy said.
Sotse Segoneco of Sonke Pharmaceuticals said they are grateful to have been afforded the opportunity to assist the government in reducing new HIV infections by providing affordable, quality generic ARV medication to people in South Africa.
Ranbaxy Laboratories managing director Arun Sawhney said they are humbled to be given this responsibility to produce, supply and distribute affordable ARVs in South Africa.
"As a socially responsible global pharmaceutical company, we are committed to the cause of alleviating the suffering due to HIV/AIDS and to bring high quality medication to those who need it the most," Sawhney said.